These medications also show little impact on the risk of dangerous thromboembolic events.
When platelet counts drop low due to underlying conditions or medical therapies like chemotherapy, the blood does not clot as it should. Clinicians frequently rely on platelet transfusions to help prevent bleeding, despite inherent complications such as fevers or potential infections. In response, medical researchers have investigated whether lysine analogues—specifically tranexamic acid (TXA) and epsilon aminocaproic acid (EACA)—could stabilize clots, reduce bleeding, and minimize reliance on donor blood products.
In Plain English: The Clinical Takeaway
- What are antifibrinolytics? These are medications that prevent blood clots from breaking down too quickly, helping the body maintain a seal over injured blood vessels.
- What does the latest evidence show?
- What remains uncertain?
Understanding Haematological Disorders and Thrombocytopenia
Haematological disorders encompass a wide spectrum of conditions affecting the blood and blood-forming organs, such as bone marrow. These diseases disrupt primary physiological functions, including oxygen transport, clotting, and immunity. Non-malignant conditions like anaemia or sickle cell anaemia sit alongside haematological malignancies such as leukaemia, lymphoma, and myeloma.
A frequent complication across these diagnoses is thrombocytopenia, defined as a low platelet count. When counts fall, people may bruise or bleed more easily. Bone marrow failure from an underlying blood disorder or the effects of chemotherapy drives this vulnerability. While platelet transfusions are used to help prevent bleeding, they carry risks, including fevers and infections transmitted to the patient from the transfused platelets.
Evaluating the Efficacy and Safety of Antifibrinolytic Agents
To explore alternatives that reduce transfusion exposure, researchers examined studies comparing TXA or EACA against placebos or no treatment. The updated body of evidence current to January 2025 incorporates eight distinct studies encompassing a total of 1,041 participants across adult and paediatric cohorts. Six of these trials evaluated TXA, while two focused on EACA.
Methodological analysis reveals significant limitations within the existing literature. For tranexamic acid, data indicates that the drug probably makes little to no difference in the incidence of moderate or worse bleeding. Similarly, it shows little measurable effect on severe, life-threatening haemorrhages or dangerous vascular clotting events known as thromboembolism. For EACA, the available data from the two designated studies was insufficient to permit an analysis of their results.
Funding sources for these investigations varied: five studies received support from governmental, academic, or other non-pharmaceutical organizations, one was backed by a pharmaceutical company, and two did not disclose funding details. The overall certainty of the evidence remains low, largely constrained by too few studies and low event rates for outcomes like death or dangerous blood clots.
| Medication | Studies Evaluated | Total Participants | Primary Clinical Outcome vs. Placebo |
|---|---|---|---|
| Tranexamic Acid (TXA) | 6 studies | ~1,000+ (across cohorts) | Probably little to no difference in moderate-to-severe bleeding or thromboembolism. |
| Epsilon Aminocaproic Acid (EACA) | 2 studies | Limited cohort data | Insufficient data available for analysis. |
Contraindications & When to Consult a Doctor
Use of agents like tranexamic acid and epsilon aminocaproic acid may involve risks, most importantly the increased risk of forming unwanted blood clots, such as deep vein thrombosis (DVT), which could be potentially life-threatening.
Future Directions in Haemostatic Management
References
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition.
